P-055: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ERYTHROCYTE PYRUVATE KINASE ACTIVATOR ETAVOPIVAT IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE.
T., C; A., LA L; R., B; T., K; J., K; J., B; C., T; K., W; S., S.
HemaSphere.
2022;
6:43-44.
O-03: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH.
M., T; R., B; R., H; M., I; I., O; T., K; F., K; J., G; P., S; E., WU; et al.
HemaSphere.
2022;
6:02-03.
Autism-associated chromatin remodeler CHD8 regulates erythroblast cytokinesis and fine-tunes the balance of Rho GTPase signaling.
Tu, Z; Fan, C; Davis, AK; Hu, M; Wang, C; Dandamudi, A; Seu, KG; Kalfa, TA; Lu, QR; Zheng, Y.
Cell Reports.
2022;
40.
Rapid degradation of protein tyrosine phosphatase 1B in sickle cells: Possible contribution to sickle cell membrane weakening.
Noomuna, P; Hausman, JM; Sansoya, R; Kalfa, T; Risinger, M; Low, PS.
FASEB Journal.
2022;
36.
Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT-4202), an Allosteric Activator of Pyruvate Kinase-R, in Healthy Adults: A Randomized, Placebo-Controlled, Double-Blind, First-in-Human Phase 1 Trial.
Forsyth, S; Schroeder, P; Geib, J; Vrishabhendra, L; Konstantinidis, DG; LaSalvia, K; Ribadeneira, MD; Wu, E; Kelly, P; Kalfa, TA.
Clinical Pharmacology in Drug Development.
2022;
11:654-665.
Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease.
Schroeder, P; Fulzele, K; Forsyth, S; Ribadeneira, MD; Guichard, S; Wilker, E; Marshall, CG; Drake, A; Fessler, R; Konstantinidis, DG; et al.
Journal of Pharmacology and Experimental Therapeutics.
2022;
380:210-219.
Altered erythropoiesis in newborns with congenital heart disease.
Tseng, SY; Gao, Z; Kalfa, TA; Ollberding, NJ; Tabbah, S; Keller, R; Cnota, JF.
Pediatric Research.
2022;
91:606-611.